Jazz Pharmaceuticals price target raised to $205 from $162 at Citi. Citi analyst Liav Abraham raised her price target for Jazz Pharmaceuticals to $205 and keeps a Buy rating on the shares. The analyst remains a constructive stance on Jazz given the potential for upside to consensus estimates. Further, balance sheet optionality can support business development and drive revenue diversification, Abraham tells investors in a research note. The analyst also has increased confidence in the commercial opportunity for solriamfetol.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.